Item 1A. Risk Factors.
An investment in our securities involves a high
degree of risk. You should consider carefully all of the material risks described below, together with the other information contained
in this Form 10-K. If any of the following events occur, our business, financial condition, results of operations and cash flows may be
materially adversely affected.
Risks Related to the Company’s Business and Industry
We will require substantial funding, which may not be available
to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.
We are using the proceeds from our IPO and subsequent
funding to, among other uses, advance Berubicin through clinical development. Developing pharmaceutical products, including conducting
preclinical studies and clinical trials, is expensive. We will require substantial additional future capital in order to complete clinical
development and commercialize Berubicin. If the FDA requires that we perform additional nonclinical studies or clinical trials, our expenses
would further increase beyond what we currently expect and the anticipated timing of any potential approval of Berubicin would likely
be delayed. Further, there can be no assurance that the costs we will need to incur to obtain regulatory approval of Berubicin will not
increase.
We will continue to require substantial additional
capital to continue our clinical development and commercialization activities. Because successful development of our product candidates
is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and development and commercialize
our products under development.
We estimate that we will require additional
financing of approximately $12.0 to $16.0 million to complete the Phase 2 trial for Berubicin, approximately $4.0 million to support
near-term WP1244/WP1874 preclinical work, plus such additional working capital to fund our operations during the pendency of the
trial. The timing and costs of clinical trials are difficult to predict and as such the foregoing estimates may prove to be
inaccurate. We have no commitments for such additional needed financing and will likely be required to raise such financing through
the sale of additional equity or debt securities.
The amount and timing of our future funding requirements
will depend on many factors, including but not limited to:
· whether our plan for clinical trials will be completed on a timely basis;
· market acceptance of our product candidates;
· the effect of competing drug candidates and new product approvals;
Some of these factors are outside of our control.
We may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization,
marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional funding may
not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the
rights of our stockholders.
If we are unable to obtain funding on a timely
basis, we may be required to significantly curtail one or more of our research or development programs. We also could be required to seek
funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of our technologies
or product candidates or otherwise agree to terms unfavorable to us.
The report of our independent registered public accounting firm
expresses substantial doubt about our ability to continue as a going concern. Such “going concern” opinion could impair our
ability to obtain financing.
Our auditors have indicated in their report on
our financial statements for the fiscal year ended December 31, 2021 that conditions exist that raise substantial doubt about our ability
to continue as a going concern due to our recurring losses from operations. A “going concern” opinion could impair our ability
to finance our operations through the sale of equity, incurring debt, or other financing alternatives. Our ability to continue as a going
concern will depend upon the availability and terms of future funding. If we are unable to achieve this goal, our business would be jeopardized
and we may not be able to continue. If we ceased operations, it is likely that all of our investors would lose their investment.
We have in the past completed related party transactions, some of
which that were not conducted on an arm’s length basis.
We have entered into transactions with entities
affiliated with our founder and significant shareholder, Dr. Waldemar Priebe, including:
We entered into the above agreements related to
Berubicin with HPI and WPD prior to our IPO, at a time during which we did not have an independent board of directors. As such, due to
the related party relationship between our Company and these entities, the negotiation of these agreements was not conducted on an arm’s
length basis. As such, it is possible that the terms were less favorable to us than in a transaction negotiated in an arm’s length
transaction.
We have never been profitable, we have no products approved for
commercial sale, and we have not generated any revenue from product sales. As a result, our ability to reduce our losses and reach profitability
is unproven, and we may never achieve or sustain profitability. Therefore, we may not be able to continue as a going concern.
We have never been profitable and do not expect
to be profitable in the foreseeable future. We have not yet submitted any drug candidates for approval by regulatory authorities in the
United States or elsewhere. Our ability to continue as a going concern is dependent upon our generating cash flow from sales that are
sufficient to fund operations or finding adequate financing to support our operations. To date, we have had no revenues and have relied
on equity-based financing from the sale of securities in public and private placements and the issuance of convertible notes. The continuation
of the Company as a going concern is dependent upon our ability to obtain continued financial support from its stockholders, necessary
equity or debt financing to continue operations and the attainment of profitable operations. As of December 31, 2021 the Company has incurred
an accumulated deficit of $34,982,921 since inception and had not yet generated any revenue from operations. Additionally, management
anticipates that its cash on hand as of December 31, 2021 is sufficient to fund its planned operations through but not beyond calendar
year 2022.
To date, we have devoted most of our financial
resources to corporate overhead, preparing for and conducting the clinical trial and marketing of our securities. We have not generated
any revenues from product sales. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase
as we continue our development of and seek regulatory approvals for Berubicin and WP1244/WP1874, prepare for and begin the commercialization
of any approved products, and add infrastructure and personnel to support our continuing product development efforts. We anticipate that
any such losses could be significant for the next several years. If Berubicin or any of our other drug candidates fail in clinical trials
or do not gain regulatory approval, or if our drug candidates do not achieve market acceptance, we may never become profitable. As a result
of the foregoing, we expect to continue to experience net losses and negative cash flows for the foreseeable future. These net losses
and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital.
Because of the numerous risks and uncertainties
associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or
when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA to perform
studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development
of any of our drug candidates. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and
our ability to generate revenues.
We have a limited operating history and we expect a number of factors
to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance.
We are a clinical pharmaceutical company with limited
operating history. Our operations to date have been limited to acquiring our technology portfolio, preparing for and conducting our Berubicin
clinical trial, and pre-clinical work related to other drug candidate, WP1244/WP1874. We have not yet obtained any regulatory approvals
for any of our drug candidates. Consequently, any predictions made about our future success or viability may not be as accurate as they
could be if we had a longer operating history or approved products on the market. Our operating results are expected to significantly
fluctuate from quarter to quarter or year to year due to a variety of factors, many of which are beyond our control. Factors relating
to our business that may contribute to these fluctuations include:
· delays in the commencement, enrollment and timing of clinical trials;
· difficulties in identifying patients suffering from our target indications;
· the success of our clinical trials through all phases of clinical development;
· our ability to obtain additional funding to develop drug candidates;
· competition from existing products or new products that continue to emerge;
· potential product liability claims.
These factors are our best estimates of possible
factors but cannot be considered a complete recitation of possible factors that could affect the Company. Accordingly, the results of
any historical quarterly or annual periods should not be relied upon as indications of future operating performance.
We cannot be certain that Berubicin will receive regulatory approval,
and without regulatory approval we will not be able to market Berubicin.
Our business currently depends largely on the successful
development and commercialization of Berubicin. Our ability to generate revenue related to product sales, if ever, will depend on the
successful development and regulatory approval of Berubicin for the treatment of glioblastoma.
We currently have no products approved for sale
and we cannot guarantee that we will ever have marketable products. The development of a product candidate and issues relating to its
approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in other countries,
with regulations differing from country to country. We are not permitted to market our product candidates in the United States until we
receive approval of an NDA from the FDA. We have not submitted any marketing applications for any of our product candidates.
NDAs must include extensive preclinical and clinical
data and supporting information to establish the product candidate’s safety and effectiveness for each desired indication. NDAs
must also include significant information regarding the chemistry, manufacturing and controls for the product. Obtaining approval of an
NDA is a lengthy, expensive, and uncertain process, and we may not be successful in obtaining approval. The FDA review processes can take
years to complete, and approval is never guaranteed. If we submit an NDA to the FDA, the FDA must decide whether to accept or reject the
submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators in other
jurisdictions have their own procedures for approval of product candidates. Even if a product is approved, the FDA may limit the indications
for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical
trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and Europe also have requirements
for approval of drug candidates with which we must comply with prior to marketing in those countries. Obtaining regulatory approval for
marketing of a product candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country.
In addition, delays in approvals or rejections of marketing applications in the United States, Europe or other countries may be based
upon many factors, including regulatory requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory
questions regarding different interpretations of data and results, changes in regulatory policy during the period of product development
and the emergence of new information regarding our product candidates or other products. Also, regulatory approval for any of our product
candidates may be withdrawn.
If we are unable to obtain approval from the FDA,
or other regulatory agencies, for Berubicin and our other product candidates, or if, subsequent to approval, we are unable to successfully
commercialize Berubicin or our other product candidates, we will not be able to generate sufficient revenue to become profitable or to
continue our operations, likely resulting in the total loss of principal for our investors.
Any statements in this filing indicating that Berubicin
has demonstrated preliminary evidence of efficacy are our own and are not based on the FDA’s or any other comparable governmental
agency’s assessment of Berubicin and do not indicate that Berubicin will achieve favorable efficacy results in any later stage trials
or that the FDA or any comparable agency will ultimately determine that Berubicin is effective for purposes of granting marketing approval.
Delays in the commencement, enrollment and completion of clinical
trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for Berubicin and our other
product candidates.
Delays in the commencement, enrollment and completion
of clinical trials could increase our product development costs or limit the regulatory approval of our product candidates. We do not
know whether any future trials or studies of our other product candidates will begin on time or will be completed on schedule, if at all.
The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, including
delays or shortages in available drug product, required clinical trial administrative actions, slower than anticipated patient enrollment,
changing standards of care, availability or prevalence of use of a comparative drug or required prior therapy, clinical outcomes or financial
constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in
increased costs, longer development times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment
of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to treat and
who meet other eligibility criteria. The rates of patient enrollment are affected by many factors, including the size of the patient population,
the eligibility criteria for the clinical trial, that include the age and condition of the patients and the stage and severity of disease,
the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments and/or availability
of investigational treatment options for the relevant disease.
A product candidate can unexpectedly fail at any
stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific feasibility,
safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or early clinical trials
of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. We,
the FDA or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons,
including, but not limited to, a belief that subjects participating in such trials are being exposed to unacceptable health risks or adverse
side effects, or other adverse initial experiences or findings. We may not have the financial resources to continue development of, or
to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory
approval of, or our ability to commercialize, product candidates, including, but not limited to:
· inability to obtain sufficient funds required for a clinical trial;
· high dropout rates and high fail rates of research subjects;
· greater than anticipated clinical trial costs;
· poor effectiveness of our product candidates during clinical trials; or
We have never conducted a clinical trial or submitted an NDA before,
and any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory
approval.
Clinical failure can occur at any stage of our
clinical development. Clinical trials may produce negative or inconclusive results, and our collaborators or we may decide, or regulators
may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials and studies are susceptible
to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory
approval. Success in preclinical studies and early clinical trials does not ensure that subsequent clinical trials will generate the same
or similar results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Many companies in
the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in clinical
trials, even after seeing promising results in earlier clinical trials.
In addition, the design of a clinical trial can
determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until
the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. Further,
clinical trials of potential products often reveal that it is not practical or feasible to continue development efforts.
If Berubicin is found to be unsafe or lack efficacy, we will not
be able to obtain regulatory approval for it and our business would be materially and possibly irreparably harmed.
In some instances, there can be significant variability
in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in
trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols and
the rate of dropout among clinical trial participants. We do not know whether any clinical trials we or any of our potential future collaborators
may conduct will demonstrate the consistent or adequate efficacy and safety that would be required to obtain regulatory approval and market
any products. If we are unable to bring Berubicin to market, or to acquire other products that are on the market or can be developed,
our ability to create long-term stockholder value will be limited.
Interim or preliminary data from our clinical trials that we announce
or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that
could result in material changes in the final data.
We may publicly disclose preliminary data from
our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions
are subject to change following a full analysis of all data related to the particular trial. We also make assumptions, estimations, calculations,
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all
data. As a result, the preliminary results that we report may differ from future results of the same trials, or different conclusions
or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary data also remain subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, preliminary data should be viewed with caution until the final data are available. We may also disclose interim
data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the
clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between
preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of preliminary or interim
data by us could result in volatility in the price of shares of our common stock.
In addition, others, including regulatory agencies,
may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance
of data differently, which could impact the approvability of the particular drug candidate and our business in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information,
and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure,
and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views,
activities or otherwise regarding a particular drug candidate or our business. If the interim data that we report differ from actual results,
or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize
our current or any our future drug candidate, our business, operating results, prospects or financial condition may be materially harmed.
The COVID-19 outbreak may delay recruitment in our clinical trials
and may continue or worsen, may affect the business of the FDA, EMA or other health authorities, which could result in delays in meetings
related to our planned clinical trials and ultimately of reviews and approvals of our product candidates.
The COVID-19 outbreak may delay recruitment in
clinical trials and may continue or worsen. Additionally, it may delay the approvals of our product candidates due to its effect on the
business of the FDA, EMA or other health authorities, which could result in delays in meetings related to planned clinical trials. The
spread of COVID-19 may also slow potential enrollment of clinical trials and reduce the number of eligible patients for our clinical trials.
The COVID-19 outbreak and mitigation measures also have had and may continue to have an adverse impact on global economic conditions which
could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The
extent to which the COVID-19 outbreak impacts our business and operations will depend on future developments that are highly uncertain
and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its
impact.
Our product candidates may have undesirable side effects that may
delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety
warnings or otherwise limit their sales.
Unforeseen side effects from any of our product
candidates could arise either during clinical development or, if Berubicin (or our other product candidates) are approved, after the approved
product has been marketed. The range and potential severity of possible side effects from therapies such as Berubicin (or our other product
candidates) are significant. If Berubicin (or our other product candidates) causes undesirable or unacceptable side effects in the future,
this could interrupt, delay or halt clinical trials and result in the failure to obtain or suspension or termination of marketing approval
from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities only with
restrictive label warnings.
If any of our product candidates receives marketing
approval and we or others later identify undesirable or unacceptable side effects caused by such products:
· we may be subject to limitations on how we may promote the product;
· sales of the product may decrease significantly;
· we may be subject to litigation or product liability claims; and
· our reputation may suffer.
Any of these events could prevent us or our potential
future collaborators from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization
costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our products.
If the FDA does not find the manufacturing facilities of our future
contract manufacturers acceptable for commercial production, we may not be able to commercialize any of our product candidates, or such
commercialization efforts may be delayed until we can contract with manufacturers with facilities acceptable to the FDA or other regulatory
authorities.
We do not have any manufacturing capabilities and
we do not intend to manufacture the pharmaceutical products that we plan to sell. We utilize contract manufacturers for the production
of the active pharmaceutical ingredients and the formulation of drug product for our pre-clinical development and clinical trials of Berubicin
that we will need to conduct prior to seeking regulatory approval. However, we do not have agreements for supplies of Berubicin or any
of our other product candidates and we may not be able to reach agreements with these or other contract manufacturers for sufficient supplies
to commercialize Berubicin if it is approved. Additionally, the facilities used by any contract manufacturer to manufacture Berubicin
or any of our other product candidates must be the subject of a satisfactory inspection before the FDA approves the product candidate
manufactured at that facility. We will be completely dependent on these third-party manufacturers for compliance with the requirements
of U.S. and non-U.S. regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material
that conform to our specifications and the FDA’s current good manufacturing practice standards, or cGMP, and other requirements
of any governmental agency whose jurisdiction to which we are subject, our product candidates will not be approved or, if already approved,
may be subject to recalls. Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our
product candidates, including:
Any of these factors could cause the delay of approval
or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates
successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial
quantities of finished product on a timely basis at commercially reasonable prices and we are unable to find one or more replacement manufacturers
capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would
likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative
source of supply for our product candidates and to have any such new source approved by the government agencies that regulate our products.
We have no sales, marketing or distribution experience and we will
have to invest significant resources to develop those capabilities or enter into third-party sales and marketing arrangements, the problems
with which could materially harm our business at any time.
We have no sales, marketing, or distribution experience.
To develop sales, distribution, and marketing capabilities, we will have to invest significant amounts of financial and management resources,
some of which will need to be committed prior to any confirmation that Berubicin or any of our other product candidates will be approved
by the FDA. For product candidates where we decide to perform sales, marketing, and distribution functions ourselves or through third
parties, we could face a number of additional risks, including that we or our third-party sales collaborators may not be able to build
and maintain an effective marketing or sales force. If we use third parties to market and sell our products, we may have limited or no
control over their sales, marketing and distribution activities on which our future revenues may depend.
We may not be successful in establishing and maintaining development
and commercialization collaborations, which could adversely affect our ability to develop certain of our product candidates and our financial
condition and operating results.
Because developing pharmaceutical products, conducting
clinical trials, obtaining regulatory approval, establishing manufacturing capabilities and marketing approved products are expensive,
we may seek to enter into collaborations with companies that have more experience. Additionally, if any of our product candidates receives
marketing approval, we may enter into sales and marketing arrangements with third parties with respect to our unlicensed territories.
If we are unable to enter into arrangements on acceptable terms, if at all, we may be unable to effectively market and sell our products
in our target markets. We expect to face competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex
and time consuming to negotiate, document and implement and they may require substantial resources to maintain. We may not be successful
in our efforts to establish and implement collaborations or other alternative arrangements for the development of our product candidates.
One or more of our collaboration partners may not
devote sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization. The terms
of any collaboration or other arrangement that we establish may contain provisions that are not favorable to us, or the favorability of
which is dependent on conditions that are out of our control or unknowable at the time of execution. In addition, any collaboration that
we enter into may be unsuccessful in the development and commercialization of our product candidates. In some cases, we may be responsible
for continuing preclinical and initial clinical development of a product candidate or research program under a collaboration arrangement,
and the payment we receive from our collaboration partner may be insufficient to cover the cost of this development. If we are unable
to reach agreements with suitable collaborators for our product candidates, we would face increased costs, we may be forced to limit the
number of our product candidates we can commercially develop or the territories in which we commercialize them. As a result, we might
fail to commercialize products or programs for which a suitable collaborator cannot be found. If we fail to achieve successful collaborations,
our operating results and financial condition could be materially and adversely affected.
Our success depends greatly on the success of Berubicin’s
development for the treatment of glioblastoma, and our pipeline of product candidates beyond this lead indication is extremely early stage
and limited.
Other than Berubicin, we do not have any other
clinical-stage drug candidates in our portfolio. As such, we are dependent on the success of Berubicin in the near term. We cannot provide
you any assurance that we will be able to successfully advance Berubicin through the development process.
We face competition from other biotechnology and pharmaceutical
companies and our operating results will suffer if we fail to compete effectively.
The biotechnology and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. We have competitors in the United States, Europe,
and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical
and generic drug companies and universities and other research institutions. Many of our competitors have greater financial and other
resources, such as larger research and development staff and more experienced marketing and manufacturing organizations than we do. Large
pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients
and manufacturing pharmaceutical products. These companies also have significantly greater research, sales and marketing capabilities
and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies
may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the
product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection
and/or FDA approval or discovering, developing and commercializing drugs for the diseases that we are targeting before we do or may develop
drugs that are deemed to be more effective or gain greater market acceptance than ours. Smaller or early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition, many universities
and private and public research institutes may become active in our target disease areas. Our competitors may succeed in developing, acquiring,
or licensing on an exclusive basis, technologies and drug products that are more effective or less costly than any of our product candidates
that we are currently developing or that we may develop, which could render our products obsolete or noncompetitive.
If our competitors market products that are more
effective, safer or less expensive or that reach the market sooner than our future products, if any, we may not achieve commercial success.
In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes in each technology. If
we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products
developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.
Our licensed U.S. patents expired in March 2020, the expiration
of our patents may subject us to increased competition, and the Orphan Drug Designation we received for Berubicin will not bar approval
of other similar products under certain circumstances.
The U.S. patents for Berubicin that we licensed
from HPI expired in March 2020, and such expiration may subject us to increased competition. On June 10, 2020, the FDA granted Orphan
Drug Designation (“ODD”) for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available for drugs targeting
diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of an NDA in the
United States. During that period the FDA generally could not approve another product containing the same drug for the same designated
indication. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product
with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater
efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet
market demand. The ODD now constitutes our primary intellectual property protections although we are exploring if there are other patents
that could be filed related to Berubicin to extend additional protections. However, we can provide no assurance that we will be able to
file or receive additional patent protection. The failure to obtain additional patent protection will reduce the barrier to entry for
competition for Berubicin, which may adversely affect our operations.
We may incur substantial costs as a result of litigation or other
proceedings relating to patent and other intellectual property rights.
We may from time to time seek to enforce our intellectual
property rights against infringers when we determine that a successful outcome is probable and may lead to an increase in the value of
the intellectual property. If we choose to enforce our patent rights against a party, then that individual or company has the right to
ask the court to rule that such patents are invalid or should not be enforced. Additionally, the validity of our patents and the patents
we have licensed may be challenged if a petition for post grant proceedings such as interpartes review and post grant review is filed
within the statutorily applicable time with the U.S. Patent and Trademark Office (USPTO). These lawsuits and proceedings are expensive
and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping
the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid and that we
do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of such patents
is upheld, the court will refuse to stop the other party on the ground that such other party’s activities do not infringe our intellectual
property rights. In addition, in recent years the U.S. Supreme Court modified some tests used by the USPTO in granting patents over the
past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of a challenge of
any patents we obtain or license.
We may be subject to claims that our employees and contractors have
wrongfully used or disclosed alleged trade secrets of their former employers.
As is common in the biotechnology and pharmaceutical
industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. We may be subject to claims that these employees, or we, have used or disclosed trade secrets or other proprietary
information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending
against these claims, litigation could result in substantial costs and be a distraction to management.
If we are not able to adequately prevent disclosure of trade secrets
and other proprietary information, the value of our technology and products could be significantly diminished.
We rely on trade secrets to protect our proprietary
technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, and other
advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others
may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce
and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our
competitive business position.
We will need to expand our operations and increase the size of our
Company, and we may experience difficulties in managing growth.
As of February 11, 2022, we have 3 full-time employees.
We also have 2 officers serving as part-time employees. As we advance our product candidates through preclinical studies and clinical
trials, we will need to increase our product development, scientific and administrative headcount to manage these programs. In addition,
to meet our obligations as a public company, we may need to increase our general and administrative capabilities. Our management, personnel,
and systems currently in place may not be adequate to support this future growth. If we are unable to successfully manage this growth
and increased complexity of operations, our business may be adversely affected.
We may not be able to manage our business effectively if we are
unable to attract and retain key personnel and consultants.
We may not be able to attract or retain qualified
management, finance, scientific and clinical personnel, and consultants due to the intense competition for qualified personnel and consultants
among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel and consultants
to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development
objectives, our ability to raise additional capital.
We are highly dependent on the development, regulatory,
commercialization and business development expertise of our management team, key employees, and consultants. If we lose one or more of
our executive officers or key employees or consultants, our ability to implement our business strategy successfully could be seriously
harmed. Any of our executive officers or key employees or consultants may terminate their employment at any time. Replacing executive
officers, key employees and consultants may be difficult and may take an extended period of time because of the limited number of individuals
in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products
successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire,
train, retain or motivate these additional key personnel and consultants. Our failure to retain key personnel or consultants could materially
harm our business.
In addition, we have scientific and clinical advisors
and consultants who assist us in formulating our research, development, and clinical strategies. These advisors are not our employees
and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us and typically
they will not enter into noncompete agreements with us. If a conflict of interest arises between their work for us and their work for
another entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with ours.
Our chief medical officer and chief science officer are currently
working for us on a part-time basis. Our chief executive officer, chief medical officer and chief science officer, also provide services
for other companies in our industry and such other positions may create conflicts of interest for such officers in the future.
Certain of our key employees are currently part-time
and/or provide services for other biotechnology development efforts, including companies, with respect to our chief executive officer
and chief medical officer, which are developing anti-cancer drug candidates. Specifically, John M. Climaco, our chairman and chief executive
officer, is also serving as a director for Moleculin Biotech, Inc., a company also actively developing anticancer drugs. Sandra Silberman,
our chief medical officer, is also the chief medical officer for New Products at Moleculin. Donald Picker, our chief science officer,
is the chief scientific officer at Moleculin.
In addition to our officers’ part-time status,
since Mr. Climaco, Dr. Silberman and Dr. Picker are associated with other companies that are developing anti-cancer drug candidates, they
may encounter conflicts of interest in the future. Although we do not believe that the drug candidates we are currently pursuing compete
with the types of drug candidates being pursued by the other companies Mr. Climaco, Dr. Silberman and Dr. Picker are associated with,
there is no assurance that such conflicts will not arise in the future.
We do not expect that our insurance policies will cover all of our
business exposures thus leaving us exposed to significant uninsured liabilities.
We do not carry insurance for all categories of
risk that our business may encounter. There can be no assurance that we will secure adequate insurance coverage or that any such insurance
coverage will be sufficient to protect our operations to significant potential liability in the future. Any significant uninsured liability
may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.
Although dependent on certain key personnel, we do not have any
key man life insurance policies on any such people.
We are dependent on John M. Climaco, Christopher
Downs, Sandra Silberman, and Donald Picker in order to conduct our operations and execute our business plan, however, we have not purchased
any insurance policies with respect to those individuals in the event of their death or disability. Therefore, if any of John M. Climaco,
Christopher Downs, Sandra Silberman, or Donald Picker die or become disabled, we will not receive any compensation to assist with such
person’s absence. The loss of such person could negatively affect us and our operations.
There are limited suppliers for active pharmaceutical ingredients
(“API”) used in our drug candidates. Problems with the third parties that manufacture the API used in our drug candidates,
or in the supply chain between the manufacturer and CNS, may delay our clinical trials or subject us to liability.
We do not currently own or operate manufacturing
facilities for clinical or commercial production of the API used in any of our drug candidates. We have no experience in API manufacturing,
and we lack the resources and the capability to manufacture any of the APIs used in our drug candidates, on either a clinical or commercial
scale. As a result, we rely on third parties to supply the API used in each of our drug candidates and commercial couriers to deliver
the manufactured API to us. We expect to continue to depend on third parties to supply the API for our current and future product candidates
and to supply the API in commercial quantities. We are ultimately responsible for confirming that the APIs used in our product candidates
are manufactured in accordance with applicable regulations.
Our third-party suppliers and couriers may not
carry out their contractual obligations or meet our deadlines. In addition, the API they supply to us may not meet our specifications
and quality policies and procedures or they may not be able to supply the API in commercial quantities. If we need to find alternative
suppliers for the API used in any of our product candidates, we may not be able to contract for such supplies on acceptable terms, if
at all. Any such failure to supply or delay caused by such contract manufacturers or couriers would have an adverse effect on our ability
to continue clinical development of our product candidates or commercialization of our product candidates.
If our third-party drug suppliers fail to achieve
and maintain high manufacturing standards in compliance with cGMP regulations, we could be subject to certain product liability claims
in the event such failure to comply resulted in defective product that caused injury or harm.
We may not be able to recover from any catastrophic event affecting
our suppliers.
Our suppliers may not have adequate measures in
place to minimize and recover from catastrophic events that may substantially destroy their capability to meet customer needs and any
measures they may have in place may not be adequate to recover production processes quickly enough to support critical timelines or market
demands. These catastrophic events may include weather and geologic events such as tornadoes, earthquakes, floods, tidal waves, volcanic
eruptions, and fires as well as infectious disease epidemics, acts of war, acts of terrorism and nationalization of private industry.
In addition, these catastrophic events may render some or all of the products at the affect facilities unusable.
We may be materially adversely affected in the event of cyber-based
attacks, network security breaches, service interruptions, or data corruption.
We rely on information technology to process and
transmit sensitive electronic information and to manage or support variety of business processes and activities. We use technology systems
to record, process, and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory
financial reporting, legal, and tax requirements. Our information technology systems, some of which are managed by third parties, may
be susceptible to damage, disruptions or shut down student computer viruses, attacks by computer hackers, failures during the process
of upgrading or replacing software, databases or components thereof, power outages, hardware failures, technology for communication failures,
user errors or catastrophic events. Although we have developed systems and processes that are designed to protect proprietary or confidential
information and prevent data loss and other security breaches, such measures cannot provide absolute security. If our systems are breached
or suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and
operating results may significantly suffer and we may be subject to litigation, government enforcement actions or potential liability.
Security breaches could also cause us to incur significant remediation costs, result in product development delays, disrupt key business
operations, including development of our product candidates, and divert attention of management and key information technology resources.
Risks Related to Our Common Stock
Failure to maintain effective internal control over our financial
reporting in accordance with Section 404 of the Sarbanes-Oxley Act could cause our financial reports to be inaccurate.
We are required pursuant to Section 404 of the
Sarbanes-Oxley Act of 2002, or Section 404, to maintain internal control over financial reporting and to assess and report on the effectiveness
of those controls. This assessment includes disclosure of any material weaknesses identified by our management in our internal control
over financial reporting. Our management concluded that our internal controls over financial reporting were, and continue to be, ineffective
as of December 31, 2021, identified a material weakness in our internal controls due to the lack of sufficient personnel to allow for
segregation of duties (resulting from the limited number of personnel available) and the lack of formal documentation of our control environment.
While management is working to remediate the material weaknesses, there is no assurance that such changes, when
economically feasible and sustainable, will remediate the identified material weaknesses or that the controls will prevent or detect future
material weaknesses. If we are not able to maintain effective internal control over financial reporting, our financial statements, including
related disclosures, may be inaccurate, which could have a material adverse effect on our business.
Failure to continue improving our accounting systems and controls
could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.
As a public company, we operate in an increasingly
demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, and the related rules and regulations
of the SEC. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal
control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable
financial reports and are important to help prevent financial fraud.
Management performed an annual assessment as of
December 31, 2021 of the effectiveness of our internal control over financial reporting for its annual report. Our management concluded
that our internal control over financial reporting was, and continues to be, ineffective as of December 31, 2021, due to a material weakness
in our internal controls due to the lack of segregation of duties (resulting from the limited number of personnel available)
and the lack of formal documentation of our control environment. For as long as we remain an “emerging growth company” as
defined in the JOBS Act, we have and intend to consider to take advantage of certain exemptions from various reporting requirements that
are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being
required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. We may continue to take advantage
of these reporting exemptions until we are no longer an “emerging growth company.” To remediate these material weaknesses,
we engaged an outside firm to assist management with such accounting and will continue to use outside firms as a resource to deal with
other non-recurring or unusual transactions. However, notwithstanding our remediation efforts, there is no assurance we will not encounter
accounting errors in the future. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations
could be harmed, and investors could lose confidence in our reported financial information.
Our executive officers, directors, major stockholder and their respective
affiliates exercise significant control over us, which will limit our stockholders ability to influence corporate matters and could delay
or prevent a change in corporate control.
The holdings of our executive officers, directors,
founder and their affiliates, are, in the aggregate, approximately 23.0% of our outstanding common stock as of February 11, 2022. As a
result, these stockholders will be able to influence our management and affairs and may control the outcome of matters submitted to our
stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all
of our assets.
These stockholders acquired their shares of common
stock for substantially less than the price of the shares of common stock at the time of this report, and these stockholders may have
interests, with respect to their common stock, that are different from those of our other stockholders and the concentration of voting
power among one or more of these stockholders may have an adverse effect on the price of our common stock.
In addition, this concentration of ownership might
adversely affect the market price of our common stock by: (1) delaying, deferring or preventing a change of control of our Company; (2)
impeding a merger, consolidation, takeover or other business combination involving our Company; or (3) discouraging a potential acquirer
from making a tender offer or otherwise attempting to obtain control of our Company.
Our current stockholders’ ownership may be diluted if additional
capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.
We intend to seek to raise additional funds, finance
acquisitions or develop strategic relationships by issuing equity or convertible debt securities, which would reduce the percentage ownership
of our existing stockholders. Our board of directors has the authority, without action or vote of the stockholders, to issue all or any
part of our authorized but unissued shares of common or preferred stock. Our articles of incorporation authorize us to issue up to 75,000,000
shares of common stock and 5,000,000 shares of preferred stock. Future issuances of common or preferred stock would reduce your influence
over matters on which stockholders vote and would be dilutive to earnings per share. In addition, any newly issued preferred stock could
have rights, preferences, and privileges senior to those of the common stock. Those rights, preferences, and privileges could include,
among other things, the establishment of dividends that must be paid prior to declaring or paying dividends or other distributions to
holders of our common stock or providing for preferential liquidation rights. These rights, preferences and privileges could negatively
affect the rights of holders of our common stock, and the right to convert such preferred stock into shares of our common stock at a rate
or price that would have a dilutive effect on the outstanding shares of our common stock.
In May 2020, the SEC issued an order suspending the trading of our
common stock and Nasdaq issued a trading halt in our common stock.
On May 1, 2020, the SEC, pursuant to Section 12(k)
of the Exchange Act, ordered the temporary suspension of trading in our securities because of questions regarding the accuracy and adequacy
of information in the marketplace about us and our securities. Pursuant to the suspension order, the suspension commenced at 9:30 a.m.
EDT on May 4, 2020 and terminated at 11:59 p.m. EDT on May 15, 2020. On May 15, 2020, Nasdaq issued a trading halt in our common stock
pending the receipt of requested information, which halt was released on May 28, 2020. We believe in the accuracy and adequacy of our
public disclosures, but can provide no assurances that we will not encounter future similar actions, which may adversely affect the holders
of our common stock.
Our currently authorized but unissued shares may be insufficient
to raise the capital needed to continue our development program.
As of March 3, 2022,
we had 40,032,481 shares of common stock outstanding, 19,790,240 shares of common stock reserved for future issuance pursuant to granted
options and warrants, and 2,135,264 shares reserved for future issuance pursuant to future grants under our equity compensation plans.
Accordingly, of our 75,000,000 authorized shares of common stock, we have 15,177,279 shares of common stock available for future financings.
We will need to raise additional financing in order to complete our ongoing clinical trial of Berubicin. If we do not sufficient available
shares of common stock for such financings, we may not be able to raise sufficient capital to fund our operations.
If we are unable to maintain compliance with the listing requirements
of The Nasdaq Capital Market, our common stock may be delisted from The Nasdaq Capital Market which could have a material adverse effect
on our financial condition and could make it more difficult for you to sell your shares.
Our common stock is listed on The Nasdaq Capital
Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of
publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholder's equity, among others, and
requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from
The Nasdaq Capital Market.
Pursuant to NASDAQ Listing Rule 5550(a)(2), we
are not currently in compliance with the $1.00 minimum closing bid price requirement set forth in such rule as our stock price is currently
trading below $1.00 and has been below such threshold since January 6, 2022. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we
have been provided an initial period of 180 calendar days, or until August 17, 2022, to regain compliance with the bid price requirements.
If, at any time before August 17, 2022, the bid price for our common stock closes at $1.00 or more for a minimum of 10 consecutive business
days as required under Nasdaq Listing Rules, the Nasdaq staff will provide written notification to us that we complied with the bid price
rule, unless the staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If we are
not in compliance with the bid price rule by August 17, 2022, we may be afforded a second 180 calendar day period to regain compliance.
To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other initial
listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, we would be required to notify
Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split. If
we do not regain compliance with the bid price rule by the above deadline and if we are not eligible for an additional compliance period
at that time, the Nasdaq staff will provide written notification to us that our common stock may be delisted. We would then be entitled
to appeal the staff’s determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be no assurance that,
if we do appeal the delisting determination by the staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful.
Delisting from The Nasdaq Capital Market would
adversely affect our ability to raise additional financing through the public or private sale of equity securities, may significantly
affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting
also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest
in business development opportunities.
General Risk Factors
As a biotechnology company, we may be at an increased risk of securities
class action litigation.
Historically, securities class action litigation
has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for
us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were
to be sued, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.
If securities or industry analysts do not publish research or reports
about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could
decline.
The trading market for our common stock will be
influenced by the research and reports that industry or securities analysts publish about us, our industry and our market. If no analyst
elects to cover us and publish research or reports about us, the market for our common stock could be severely limited and our stock price
could be adversely affected. As a small-cap company, we are more likely than our larger competitors to lack coverage from securities analysts.
In addition, even if we receive analyst coverage, if one or more analysts ceases coverage of us or fails to regularly publish reports
on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. If one
or more analysts who elect to cover us issue negative reports or adversely change their recommendations regarding our common stock, our
stock price could decline.